HRP970432B1 - Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives - Google Patents

Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Info

Publication number
HRP970432B1
HRP970432B1 HR970432A HRP970432A HRP970432B1 HR P970432 B1 HRP970432 B1 HR P970432B1 HR 970432 A HR970432 A HR 970432A HR P970432 A HRP970432 A HR P970432A HR P970432 B1 HRP970432 B1 HR P970432B1
Authority
HR
Croatia
Prior art keywords
pyrimido
substituted pyrido
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
HR970432A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP970432A2 publication Critical patent/HRP970432A2/hr
Publication of HRP970432B1 publication Critical patent/HRP970432B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR970432A 1996-08-06 1997-08-06 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives HRP970432B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06

Publications (2)

Publication Number Publication Date
HRP970432A2 HRP970432A2 (en) 1998-08-31
HRP970432B1 true HRP970432B1 (en) 2002-10-31

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970432A HRP970432B1 (en) 1996-08-06 1997-08-06 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Country Status (41)

Country Link
US (1) US6492520B1 (no)
EP (1) EP0920429B1 (no)
JP (1) JP3345021B2 (no)
KR (1) KR20000029843A (no)
CN (1) CN1093130C (no)
AP (1) AP1096A (no)
AR (1) AR008829A1 (no)
AT (1) ATE232863T1 (no)
AU (1) AU709203B2 (no)
BG (1) BG103143A (no)
BR (1) BR9710808A (no)
CA (1) CA2262692C (no)
CO (1) CO4900060A1 (no)
CZ (1) CZ292806B6 (no)
DE (1) DE69719193T2 (no)
DK (1) DK0920429T3 (no)
DZ (1) DZ2289A1 (no)
EA (1) EA003188B1 (no)
ES (1) ES2191183T3 (no)
GT (1) GT199700089A (no)
HK (1) HK1021734A1 (no)
HR (1) HRP970432B1 (no)
ID (1) ID17980A (no)
IL (1) IL128188A0 (no)
IS (1) IS4948A (no)
MA (1) MA24296A1 (no)
NO (1) NO313293B1 (no)
NZ (1) NZ333727A (no)
OA (1) OA10970A (no)
PA (1) PA8435201A1 (no)
PE (1) PE97098A1 (no)
PL (1) PL331602A1 (no)
SA (1) SA97180334A (no)
SK (1) SK14099A3 (no)
TN (1) TNSN97135A1 (no)
TR (1) TR199900228T2 (no)
TW (1) TW550265B (no)
UY (1) UY24655A1 (no)
WO (1) WO1998005661A1 (no)
YU (1) YU5399A (no)
ZA (1) ZA976954B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
JP2002529465A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1432711A1 (en) 2001-09-26 2004-06-30 Bayer Corporation 1,6-naphthyridine derivatives as antidiabetics
ATE370952T1 (de) * 2002-04-19 2007-09-15 Smithkline Beecham Corp Neue verbindungen
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003285614B2 (en) 2002-12-20 2009-05-14 Pfizer Products, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005020910A2 (en) * 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
EP1732541A4 (en) * 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
US20090137550A1 (en) * 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
ES2441873T3 (es) 2005-05-26 2014-02-06 Aldexa Therapeutics, Inc. Derivados de quinolina para el tratamiento de enfermedades retinianas
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
JP2009521479A (ja) 2005-12-21 2009-06-04 アボット・ラボラトリーズ 抗ウイルス化合物
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
US8476270B2 (en) 2009-09-14 2013-07-02 Gilead Sciences, Inc. Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ME02651B (me) 2012-06-13 2017-06-20 Incyte Holdings Corp Substituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20160518A (es) * 2014-05-15 2017-02-21 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
EP3848375B1 (en) 2014-09-16 2023-12-27 Gilead Sciences, Inc. Methods of preparing intermediates for toll-like receptor modulators
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
KR102664994B1 (ko) 2015-08-21 2024-05-13 알데이라 테라퓨틱스, 아이엔씨. 중수소화 화합물 및 이의 용도
RS63240B1 (sr) 2016-02-12 2022-06-30 Cytokinetics Inc Derivati tetrahidroizohinolina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
US11040039B2 (en) * 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2895961B2 (ja) * 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
CN1056611C (zh) * 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Ｉｃカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
KR100256707B1 (ko) * 1995-05-12 2000-05-15 해피 페너 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
IL123835A0 (en) 1996-02-07 1998-10-30 Janssen Pharmaceutica Nv Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
CA2262692C (en) 2002-06-11
OA10970A (en) 2001-11-05
UY24655A1 (es) 2000-09-29
TR199900228T2 (xx) 1999-03-22
NO313293B1 (no) 2002-09-09
BR9710808A (pt) 1999-08-17
PA8435201A1 (es) 1999-12-27
YU5399A (sh) 2002-03-18
JP2000501116A (ja) 2000-02-02
EA003188B1 (ru) 2003-02-27
GT199700089A (es) 1999-01-26
AP9701052A0 (en) 1997-10-31
EA199900083A1 (ru) 1999-08-26
AR008829A1 (es) 2000-02-23
MA24296A1 (fr) 1998-04-01
NO990544L (no) 1999-03-31
PL331602A1 (en) 1999-08-02
NO990544D0 (no) 1999-02-05
CO4900060A1 (es) 2000-03-27
EP0920429B1 (en) 2003-02-19
PE97098A1 (es) 1999-01-12
BG103143A (en) 1999-09-30
DZ2289A1 (fr) 2002-12-25
IL128188A0 (en) 1999-11-30
CN1227552A (zh) 1999-09-01
AU709203B2 (en) 1999-08-26
ES2191183T3 (es) 2003-09-01
HRP970432A2 (en) 1998-08-31
US6492520B1 (en) 2002-12-10
DE69719193T2 (de) 2003-09-25
CZ41199A3 (cs) 2000-01-12
SA97180334A (ar) 2005-12-03
ZA976954B (en) 1999-02-05
AP1096A (en) 2002-08-26
KR20000029843A (ko) 2000-05-25
IS4948A (is) 1999-01-19
TNSN97135A1 (fr) 2005-03-15
CN1093130C (zh) 2002-10-23
ID17980A (id) 1998-02-12
DK0920429T3 (da) 2003-05-12
NZ333727A (en) 2000-09-29
EP0920429A1 (en) 1999-06-09
JP3345021B2 (ja) 2002-11-18
SK14099A3 (en) 2000-05-16
TW550265B (en) 2003-09-01
CA2262692A1 (en) 1998-02-12
HK1021734A1 (en) 2000-06-30
ATE232863T1 (de) 2003-03-15
AU3356397A (en) 1998-02-25
DE69719193D1 (de) 2003-03-27
WO1998005661A1 (en) 1998-02-12
CZ292806B6 (cs) 2003-12-17

Similar Documents

Publication Publication Date Title
HRP970432B1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
IL127566A0 (en) Substituted 6,5-hetero- bicyclic derivatives
IL128049A0 (en) Substituted 6,6-hetero-bicyclic derivatives
IL141908A (en) 1,4-benzodiazepine derivatives
HK1018216A1 (en) New 19-nor-pregnene derivatives.
HRP970166A2 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
GB2311779B (en) 2,3 benzodiazepine derivatives
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
SG70589A1 (en) 1, 25-Dihydroxy-16, 22, 23-trisdehydro-cholecalciferol derivatives
PL330141A1 (en) Novel derivatives of 10,11-dihydro-10-oxo-5h-dibezyl(b,f)-azepin-5-carboxagmide
SI0920429T1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
HUP9903001A3 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
IL126780A0 (en) Substituted 1,3-benzodioxoles
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20030627

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20040807